Basic Science Investigation
Automatic preparation of 18F-Alfatide Ⅱ and its PET/CT imaging in prostate cancer
Chen Liping, Pan Donghui, Zhang Yu, Du Xiaoqing, He Huihui, Yang Min, Yu Chunjing
Published 2020-12-25
Cite as Chin J Nucl Med Mol Imaging, 2020, 40(12): 731-735. DOI: 10.3760/cma.j.cn321828-20191219-00295
Abstract
ObjectiveTo prepare 18F-Alfatide Ⅱ automatically based on the improved CFN-100 fluorine multifunctional module and assess its PET/CT imaging in prostate cancer patients.
MethodsA certain volume (200-500 μl) of fluoride ion was separated into the reaction tube by a fluoride ion separator and reacted with the labeled precursor l, 4, 7-triazacylononane-1, 4, 7-triacetic acid-E[(polyethylene glycol) 4-cyclo(Arg-Gly-Asp-D-Phe-Tyr)]2(NOTA-E[PEG4-c(RGDfk)]2) (lyophilized kit). In the aqueous phase, 18F was chelated with aluminum. After being separated and purified by C18 column, 18F-Alfatide Ⅱ was prepared automatically. The radiochemical yield and its quality were analyzed. Quality control was carried out and 18F-Alfatide Ⅱ PET/CT imaging was performed in 2 patients (72 and 66 years old)with prostate cancer.
Results18F-Alfatide Ⅱ was prepared automatically by the improved CFN-100 fluorine multifunctional module combined with a double channel-fluorine ion separation device. 18F-Alfatide Ⅱ was synthetized in about 30 min, with radiochemical yield of (28±3)% (non-decay corrected, n=6). The radiochemical purity of the product was more than 98%, the specific activity was 2.8×107 MBq/mmol and the nuclear purity was >99%. PET/CT imaging of 2 patients showed that 18F-Alfatide Ⅱ were highly concentrated in prostate cancer lesions with the maximum standardized uptake value (SUVmax) of 35.6 and 5.0, respectively.
Conclusion18F-Alfatide Ⅱ can be prepared successfully by improved CFN-100 fluorine multifunctional module with stable synthesis method, short synthesis time and high radiochemical yield, which can be highly concentrated in prostate cancer.
Key words:
Peptides, cyclic; Arg-Gly-Asp; Fluorine radioisotopes; Chemistry techniques, synthetic; Prostatic neoplasms; Positron-emission tomography; Tomography, X-ray computed
Contributor Information
Chen Liping
Department of Nuclear Medicine, Affiliated Hospital of Jiangnan University, the Fourth People′s Hospital of Wuxi, Wuxi 214062, China
Pan Donghui
NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, China
Zhang Yu
Department of Nuclear Medicine, Affiliated Hospital of Jiangnan University, the Fourth People′s Hospital of Wuxi, Wuxi 214062, China
Du Xiaoqing
Department of Nuclear Medicine, Affiliated Hospital of Jiangnan University, the Fourth People′s Hospital of Wuxi, Wuxi 214062, China
He Huihui
Department of Nuclear Medicine, Affiliated Hospital of Jiangnan University, the Fourth People′s Hospital of Wuxi, Wuxi 214062, China
Yang Min
NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, China
Yu Chunjing
Department of Nuclear Medicine, Affiliated Hospital of Jiangnan University, the Fourth People′s Hospital of Wuxi, Wuxi 214062, China
